Cite
HARVARD Citation
Touma, Z. et al. (n.d.). FRI0339 Sledai-2k responder index-50 is effective in demonstrating partial response in a phase 2, randomised placebo-controlled study of ustekinumab in patients with active systemic lupus erythematosus. Annals of the rheumatic diseases. pp. 705-706. [Online].